Heather Cianfrocco, OptumRx CEO

Top PBM to put Hu­mi­ra biosim­i­lars on lev­el play­ing field with Ab­b­Vie block­buster

Hu­mi­ra is the best sell­ing drug of all time. And as biosim­i­lars for the drug ven­ture on­to the open mar­ket in Jan. 2023, one of the big three PBMs is mak­ing room for the biosim­i­lars to com­pete on equal foot­ing with the brand-name ver­sion.

Unit­ed­Health Group’s PBM Op­tum­Rx — one of the largest in the US along with CVS Health and Ex­press Scripts —  sig­naled Tues­day that it will place three biosim­i­lars for the Ab­b­Vie-made drug sales king on its for­mu­la­ry, its pre­ferred list of drugs, at par­i­ty with Hu­mi­ra, al­low­ing biosim­i­lars to com­pete on the same tier as the drug it­self.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.